Our Experience Olopatadine Treatment of Allergic Conjunctivitis in Children

Abstract

The authors analyzed the treatment results of 53 patients (106 eyes) with allergic conjunctivitis. All patients received Olopatadine 0.2 % (Visallergol) in drops once a day during 1 month. All patients underwent the same tests: scraping from the conjunctiva for the presence of eosinophils, evaluation of the inflammation symptoms using 4-ball scale, biomicroscopy of cornea and conjunctiva with staining by lissamine green and tear film stability (Norn’s method). All of the above-mentioned tests were performed before the treatment, on 14-th day and after the course of therapy. The inflammatory reaction of conjunctiva, the amount of discharge in the conjunctival cavity and the staining of the conjunctiva with lissamine green decreased in all patients starting from the 14-th day of treatment. The maximal effectiveness of the drop was registered in patients with the chronic type of allergic conjunctivitis. The manifestation of the disease reduced significantly after 1 month of treatment, but it does not disappear completely. So it is necessary to continue therapy after 1 month. The laboratory methods of diagnosis confirm the effectiveness of Visallergol by disappearance of eosinophils in the conjunctiva scrapings. The secondary dry eye syndrome developed in all types of the allergic conjunctivitis and needs a long-term treatment. The maximal intensity of dry eye syndrome was registered in patients with chronic type of the allergic conjunctivitis. The drop can be used starting from 2 years old.